We're excited to announce our strategic partnership with Bio-Works Technologies to bring our products to customers globally and help enable the research and development of their transformative medicines. Our Glycap-3A glycoform purification technology can be used to streamline the development of biosimilar or novel antibodies and Fc-fusions. A common use case includes the preparation of material for critical pre-clinical in vitro and in vivo structure:function, potency, safety and efficacy studies. To learn more, check out our website: https://lnkd.in/ec-vg5Mv #antibodies #glycosylation #mabs #ivig
We are delighted to announce our commercial partnership with Zepteon, Inc. under which Bio-Works has added to its product portfolio Zepteon's advanced Glycap-3A columns for the separation of non-fucosylated, bisected GlcNAc, IgG1 and IgG3 from complex antibody mixtures of monoclonal or polyclonal IgG. Read more about the agreement here: https://lnkd.in/d6drHi3M